Overall, our study indicated that functional loss of ATP1A3, induced by the point mutation Thr794Ala, could inhibit the anti‐glioma effect of CS‐6, as well as its chemosensitizing effect for TMZ. The gene discussed is ATP1A3; the disease is glioma.